Body Fluid BIN1 as a Marker of Cardiac Health

Abstract

The present disclosure provides methods involving use of BIN1 protein levels in biological fluid of a subject in evaluating cardiac health of the subject. The method provided herein may be used to predict a risk of a poor outcome in a subject. The methods also find use in evaluating subjects for assessing patients diagnosed with heart failure. These methods are also useful in assessing therapy options and efficacy of treatment in heart failure patients.

1 - 18 . (canceled) 
     
     
         19 . A method of predicting a risk of poor cardiac outcome in a human subject diagnosed with arrhythmogenic right ventricular cardiomyopathy (ARVC) or suspected of having ARVC, the method comprising:
 measuring a cardiac BIN1 protein level in a blood, serum or plasma sample obtained from the subject wherein the measuring is performed by contacting the blood, serum or plasma sample with an anti-cardiac BIN1 antibody;   comparing the cardiac BIN1 protein level to a normal cardiac BIN1 protein level; and   predicting an increased risk of poor outcome when cardiac BIN1 protein level in the blood, serum or plasma sample is significantly decreased compared to the normal cardiac BIN1 protein level,   wherein the normal cardiac BIN1 level is obtained from assaying cardiac BIN1 protein in a blood, serum or plasma sample obtained from a healthy human.   
     
     
         20 . The method of  claim 19 , wherein the subject has been diagnosed with ARVC and the poor cardiac outcome comprises increase in severity of ARVC. 
     
     
         21 . The method of  claim 19 , wherein the poor cardiac outcome comprises ventricular arrhythmia event. 
     
     
         22 . The method of  claim 19 , wherein the poor cardiac outcome comprises heart failure. 
     
     
         23 . The method of  claim 19 , wherein the poor cardiac outcome comprises cardiac mortality. 
     
     
         24 . The method of  claim 19 , comprising measuring the cardiac BIN1 protein level in the blood sample. 
     
     
         25 . The method of  claim 19 , comprising measuring the cardiac BIN1 protein level in the serum sample. 
     
     
         26 . The method of  claim 19 , comprising measuring the cardiac BIN1 protein level in the plasma sample. 
     
     
         27 . A method for assessing cardiac health of a human subject diagnosed as having arrhythmogenic right ventricular cardiomyopathy (ARVC), the method comprising:
 measuring a cardiac BIN1 protein level in a blood, serum or plasma sample obtained from the subject, wherein the measuring is performed by contacting the blood, serum or plasma sample with an anti-cardiac BIN1 antibody;   comparing the cardiac BIN1 protein level to a normal cardiac BIN1 protein level; and   assessing the cardiac health of the subject, wherein a significantly decreased cardiac BIN1 compared to the normal BIN1 protein level is positively correlated to poor cardiac health, wherein the normal cardiac BIN1 level is obtained from assaying cardiac BIN1 protein in a blood, serum or plasma sample obtained from a healthy human.   
     
     
         28 . The method of  claim 27 , wherein the poor cardiac health comprises presence of non-acute heart failure. 
     
     
         29 . The method of  claim 27 , wherein the poor cardiac health comprises presence of severe ARVC defined as either a New York Heart Association (NYHA) Class 3 or Class 4. 
     
     
         30 . The method of  claim 27 , comprising measuring the cardiac BIN1 protein level in the blood sample. 
     
     
         31 . The method of  claim 27 , comprising measuring the cardiac BIN1 protein level in the serum sample. 
     
     
         32 . The method of  claim 27 , comprising measuring the cardiac BIN1 protein level in the plasma sample. 
     
     
         33 . A method for assessing presence of non-acute heart failure in a human subject diagnosed as having arrhythmogenic right ventricular cardiomyopathy (ARVC) or suspected of having ARVC, the method comprising:
 measuring a cardiac BIN1 protein level in a blood, serum or plasma sample obtained from the subject, wherein the measuring is performed by contacting the blood, serum or plasma sample with an anti-cardiac BIN1 antibody;   comparing the cardiac BIN1 protein level to a normal cardiac BIN1 protein level; and   assessing the presence of non-acute heart failure in the subject when the cardiac BIN1 protein level is significantly decreased compared to the normal BIN1 protein level, wherein the normal cardiac BIN1 level is obtained from assaying cardiac BIN1 protein in a blood, serum or plasma sample obtained from a healthy human.   
     
     
         34 . The method of  claim 33 , wherein the method further comprises determining a cardiac functional classification of the subject, wherein the cardiac BIN1 protein level is correlated with the cardiac functional classification. 
     
     
         35 . The method of  claim 33 , comprising measuring the cardiac BIN1 protein level in the blood sample. 
     
     
         36 . The method of  claim 33 , comprising measuring the cardiac BIN1 protein level in the serum sample. 
     
     
         37 . The method of  claim 33 , comprising measuring the cardiac BIN1 protein level in the plasma sample.